US FDA authorizes Novavax Covid vaccine for adults | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Wednesday
December 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
WEDNESDAY, DECEMBER 06, 2023
US FDA authorizes Novavax Covid vaccine for adults

Coronavirus chronicle

Reuters
14 July, 2022, 10:05 am
Last modified: 14 July, 2022, 10:06 am

Related News

  • Moderna says updated Covid vaccine is effective against newer variant
  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • Vaccine maker Novavax says 'substantial doubt' over future
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Incepta Pharma abandons Covid vaccine plan

US FDA authorizes Novavax Covid vaccine for adults

Reuters
14 July, 2022, 10:05 am
Last modified: 14 July, 2022, 10:06 am
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Photo: Reuters
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Photo: Reuters

The US Food and Drug Administration authorized the use of Novavax Inc's Covid-19 vaccine on Wednesday, clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.

Shares of Novavax rose 1.3% to $70.89 after its two-dose vaccine became the fourth Covid shot to be authorized for use in adults in the United States.

The US Centers for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.

Earlier this week, the US government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks.

More than two-thirds of the US population has been fully vaccinated with shots from Moderna Inc, Pfizer-BioNTech, or Johnson & Johnson.

US health officials hope that people who have opted not to take Pfizer and Moderna's vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax's protein-based shot.

The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.

"Today's authorization offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA's rigorous standards," FDA Commissioner Robert Califf said in a statement.

In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.

The company's initial application for US authorization of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country's market for Covid vaccines.

Novavax has projected between $4 billion and $5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.

World+Biz / USA

Novavax / Novavax Covid-19 Vaccine / Novavax Inc / Novavax vaccine / Covid vaccine / US FDA Approval / US FDA

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Prime Minister Sheikh Hasina. File Photo: UNB
    Saudi Arabia an important dev partner of Bangladesh: PM Hasina
  • Prime Minister Sheikh Hasina. Sketch: TBS
    PM Hasina 46th on Forbes list of most powerful women
  • File photo: Collected
    BNP now Jamaat's 'B-team': Quader

MOST VIEWED

  • Caption: Illustration: TBS
    Source tax on land registration cut again
  • This file photo from December 2019 shows a rider driving his motorcycle through cold wind and fog. A scene not yet visible this year. Photo: Mumit M
    Woe for seasonal crops, vegetables as winter comes late 
  • File Photo: Reuters
    $1.08 billion could be added to Bangladesh's dwindling forex reserves
  • Photo: Courtesy
    Woman entrepreneur Sangeeta Khan dies at age 62
  • 59 DSE stocks face downgrade to junk category
    59 DSE stocks face downgrade to junk category
  • Dollar pressure rises as short-term foreign debt drops $300m in October
    Dollar pressure rises as short-term foreign debt drops $300m in October

Related News

  • Moderna says updated Covid vaccine is effective against newer variant
  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • Vaccine maker Novavax says 'substantial doubt' over future
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Incepta Pharma abandons Covid vaccine plan

Features

Dhaka’s FDC,  Japan Garden City and Shia Masjid were all part of Gudaraghat once. PHOTOS:  Syed Zakir Hossain

What the remaining Gudaraghats remind us of Dhaka's long-lost water bodies

7h | Panorama
A trove of research underscores the perilous consequences of relying on plastic utensils, a narrative mirrored by the western world's pivot towards sustainable alternatives - ceramic, brass, or clay dinnerware. PHOTO: TBS

While we lose our sustainable traditions, the West pivots in the opposite direction

6h | Panorama
Ghulam Ali

Ghulam Ali: Voice that makes ghazals bloom

1d | Features
Exploring door designs: Redefining spaces and experiences

Exploring door designs: Redefining spaces and experiences

1d | Habitat

More Videos from TBS

Most Ukrainians are losing interest in going to war

Most Ukrainians are losing interest in going to war

1h | TBS World
Putin to visit UAE and Saudi Arabia

Putin to visit UAE and Saudi Arabia

3h | TBS World
Will the United States - Israel attack Yemen?

Will the United States - Israel attack Yemen?

17h | TBS World
Ukraine faces challenges in securing financing and sustaining energy infrastructure

Ukraine faces challenges in securing financing and sustaining energy infrastructure

5h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net